Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

Robyn M. Emanuel, Amylou Dueck, Holly L. Geyer, Jean Jacques Kiladjian, Stefanie Slot, Sonja Zweegman, Peter A W Te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Doehner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise BoyerGabriel Etienne, Jean Christophe Ianotto, Dana Ranta, Lydia Roy, Jean Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria L. Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Ayalew Tefferi, Ruben A. Mesa

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Purpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results: MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.

Original languageEnglish (US)
Pages (from-to)4098-4103
Number of pages6
JournalJournal of Clinical Oncology
Volume30
Issue number33
DOIs
StatePublished - Nov 20 2012

Fingerprint

Symptom Assessment
Neoplasms
Research Design
Quality of Life
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Sweat
Therapeutics
Pruritus
Abdominal Pain
Statistical Factor Analysis
Fatigue
Syntex adjuvant formulation
Weight Loss

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score : Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. / Emanuel, Robyn M.; Dueck, Amylou; Geyer, Holly L.; Kiladjian, Jean Jacques; Slot, Stefanie; Zweegman, Sonja; Te Boekhorst, Peter A W; Commandeur, Suzan; Schouten, Harry C.; Sackmann, Federico; Fuentes, Ana Kerguelen; Hernández-Maraver, Dolores; Pahl, Heike L.; Griesshammer, Martin; Stegelmann, Frank; Doehner, Konstanze; Lehmann, Thomas; Bonatz, Karin; Reiter, Andreas; Boyer, Francoise; Etienne, Gabriel; Ianotto, Jean Christophe; Ranta, Dana; Roy, Lydia; Cahn, Jean Yves; Harrison, Claire N.; Radia, Deepti; Muxi, Pablo; Maldonado, Norman; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L.; Barbui, Tiziano; Barosi, Giovanni; Vannucchi, Alessandro M.; Passamonti, Francesco; Andreasson, Bjorn; Ferarri, Maria L.; Rambaldi, Alessandro; Samuelsson, Jan; Birgegard, Gunnar; Tefferi, Ayalew; Mesa, Ruben A.

In: Journal of Clinical Oncology, Vol. 30, No. 33, 20.11.2012, p. 4098-4103.

Research output: Contribution to journalArticle

Emanuel, RM, Dueck, A, Geyer, HL, Kiladjian, JJ, Slot, S, Zweegman, S, Te Boekhorst, PAW, Commandeur, S, Schouten, HC, Sackmann, F, Fuentes, AK, Hernández-Maraver, D, Pahl, HL, Griesshammer, M, Stegelmann, F, Doehner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, JC, Ranta, D, Roy, L, Cahn, JY, Harrison, CN, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, PL, Barbui, T, Barosi, G, Vannucchi, AM, Passamonti, F, Andreasson, B, Ferarri, ML, Rambaldi, A, Samuelsson, J, Birgegard, G, Tefferi, A & Mesa, RA 2012, 'Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs', Journal of Clinical Oncology, vol. 30, no. 33, pp. 4098-4103. https://doi.org/10.1200/JCO.2012.42.3863
Emanuel, Robyn M. ; Dueck, Amylou ; Geyer, Holly L. ; Kiladjian, Jean Jacques ; Slot, Stefanie ; Zweegman, Sonja ; Te Boekhorst, Peter A W ; Commandeur, Suzan ; Schouten, Harry C. ; Sackmann, Federico ; Fuentes, Ana Kerguelen ; Hernández-Maraver, Dolores ; Pahl, Heike L. ; Griesshammer, Martin ; Stegelmann, Frank ; Doehner, Konstanze ; Lehmann, Thomas ; Bonatz, Karin ; Reiter, Andreas ; Boyer, Francoise ; Etienne, Gabriel ; Ianotto, Jean Christophe ; Ranta, Dana ; Roy, Lydia ; Cahn, Jean Yves ; Harrison, Claire N. ; Radia, Deepti ; Muxi, Pablo ; Maldonado, Norman ; Besses, Carlos ; Cervantes, Francisco ; Johansson, Peter L. ; Barbui, Tiziano ; Barosi, Giovanni ; Vannucchi, Alessandro M. ; Passamonti, Francesco ; Andreasson, Bjorn ; Ferarri, Maria L. ; Rambaldi, Alessandro ; Samuelsson, Jan ; Birgegard, Gunnar ; Tefferi, Ayalew ; Mesa, Ruben A. / Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score : Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 33. pp. 4098-4103.
@article{c74008b296374fa5940dcc63df432f81,
title = "Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs",
abstract = "Purpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results: MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.",
author = "Emanuel, {Robyn M.} and Amylou Dueck and Geyer, {Holly L.} and Kiladjian, {Jean Jacques} and Stefanie Slot and Sonja Zweegman and {Te Boekhorst}, {Peter A W} and Suzan Commandeur and Schouten, {Harry C.} and Federico Sackmann and Fuentes, {Ana Kerguelen} and Dolores Hern{\'a}ndez-Maraver and Pahl, {Heike L.} and Martin Griesshammer and Frank Stegelmann and Konstanze Doehner and Thomas Lehmann and Karin Bonatz and Andreas Reiter and Francoise Boyer and Gabriel Etienne and Ianotto, {Jean Christophe} and Dana Ranta and Lydia Roy and Cahn, {Jean Yves} and Harrison, {Claire N.} and Deepti Radia and Pablo Muxi and Norman Maldonado and Carlos Besses and Francisco Cervantes and Johansson, {Peter L.} and Tiziano Barbui and Giovanni Barosi and Vannucchi, {Alessandro M.} and Francesco Passamonti and Bjorn Andreasson and Ferarri, {Maria L.} and Alessandro Rambaldi and Jan Samuelsson and Gunnar Birgegard and Ayalew Tefferi and Mesa, {Ruben A.}",
year = "2012",
month = "11",
day = "20",
doi = "10.1200/JCO.2012.42.3863",
language = "English (US)",
volume = "30",
pages = "4098--4103",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score

T2 - Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

AU - Emanuel, Robyn M.

AU - Dueck, Amylou

AU - Geyer, Holly L.

AU - Kiladjian, Jean Jacques

AU - Slot, Stefanie

AU - Zweegman, Sonja

AU - Te Boekhorst, Peter A W

AU - Commandeur, Suzan

AU - Schouten, Harry C.

AU - Sackmann, Federico

AU - Fuentes, Ana Kerguelen

AU - Hernández-Maraver, Dolores

AU - Pahl, Heike L.

AU - Griesshammer, Martin

AU - Stegelmann, Frank

AU - Doehner, Konstanze

AU - Lehmann, Thomas

AU - Bonatz, Karin

AU - Reiter, Andreas

AU - Boyer, Francoise

AU - Etienne, Gabriel

AU - Ianotto, Jean Christophe

AU - Ranta, Dana

AU - Roy, Lydia

AU - Cahn, Jean Yves

AU - Harrison, Claire N.

AU - Radia, Deepti

AU - Muxi, Pablo

AU - Maldonado, Norman

AU - Besses, Carlos

AU - Cervantes, Francisco

AU - Johansson, Peter L.

AU - Barbui, Tiziano

AU - Barosi, Giovanni

AU - Vannucchi, Alessandro M.

AU - Passamonti, Francesco

AU - Andreasson, Bjorn

AU - Ferarri, Maria L.

AU - Rambaldi, Alessandro

AU - Samuelsson, Jan

AU - Birgegard, Gunnar

AU - Tefferi, Ayalew

AU - Mesa, Ruben A.

PY - 2012/11/20

Y1 - 2012/11/20

N2 - Purpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results: MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.

AB - Purpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results: MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.

UR - http://www.scopus.com/inward/record.url?scp=84869381382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869381382&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.42.3863

DO - 10.1200/JCO.2012.42.3863

M3 - Article

C2 - 23071245

AN - SCOPUS:84869381382

VL - 30

SP - 4098

EP - 4103

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -